BYLieve demonstrates efficacy of PIK3CA-directed treatment post CDK4/6-ihibition Presented ByProf. Hope S. Rugo, University of California San Francisco, CA, USA TrialPhase 2, BYLieve ConferenceASCO 2020 8 September, 2020 09:00
